ARTAN Bio Partners with Syenex VivoCell Platform for Precision in vivo Delivery of Next-Generation Codon Suppressors for Aging

HOUSTON and CHICAGO, June 30, 2025 /PRNewswire/ -- ARTAN Bio, a community-backed biotechnology company developing therapeutics to reverse epigenetic changes associated with aging and age-related disease, and Syenex, an open-science genetic medicines platform company, today announced a strategic collaboration to access Syenex's precision in vivo delivery technologies, the VivoCell Platform, for ARTAN's lead drug, ARTAN-102.

Under the agreement, Syenex will provide ARTAN access to the VivoCell Platform and support the development of precision in vivo delivery vehicles tailored to ARTAN's codon suppressor platform, all under a non-exclusive program license option. The goal is to accelerate the timeline of ARTAN's program from in vitro proof-of-concept to IND-enabling studies while maintaining a maximally capital-efficient path for ARTAN.

Dr. Michael Torres, Co-Founder & Chief Scientific Officer of ARTAN Bio, said, "Precise, efficient delivery is critical to maximizing the potential of ARTAN-102. Syenex's track record in delivery vehicle innovation and manufacturing scale makes them a natural partner as we progress toward IND-enabling studies."

Jay Rosanelli, Chief Executive Officer of Syenex, added, "ARTAN Bio has generated strong preclinical data on the therapeutic potential of their lead drug candidate, ARTAN-102. By combining their codon suppressor platform with our VivoCell Platform, we aim to shorten development timelines and unlock treatment options for aging and age-related disease."

Collaboration scope

• Rapid Prototyping – Platform Access to the complete VivoCell Platform including libraries of precision delivery components supported by Syenex pre-clinical scale prototyping and production support.
• Manufacturing Scale-Up – Prototypes to be transferred to Syenex CDMO partner for GMP scale-up.
• Option Rights – Non-exclusive Program License option for the clinical delivery vehicle composition.

Financial terms were not disclosed.

About ARTAN Bio
ARTAN Bio is developing first-in-class therapeutics to restore full-length, functional proteins involved in aging and age-related disease. The Company's research is supported by a decentralized scientific community of stakeholders committed to accelerating cures for aging and rare genetic diseases. For more information, visit www.artan.bio and vitarna.xyz

About Syenex
Syenex is an open-science biotechnology platform company that enables developers to program cells with precision and scale. Leveraging synthetic biology and a global network of contract development and manufacturing organizations (CDMOs), Syenex provides plug-and-play delivery platforms—spanning discovery through GMP manufacturing—so genetic medicine developers can rapidly advance ideas to clinical impact. Founded in 2022, Syenex has assembled a portfolio of cell-specific ex vivo and in vivo delivery platforms and over 50 partnerships with industry leaders across biopharma and academia. Learn more at www.syenex.com.

SOURCE Syenex